Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
NCT04621851 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260
Last updated 2025-07-29
Summary
The purpose of this study is to investigate the safety profile of TKI discontinuation in clinical practice, with particular regard on the risk of progression after treatment discontinuation.
Conditions
- Chronic Myeloid Leukemia
Sponsors & Collaborators
-
University of Milano Bicocca
lead OTHER
Principal Investigators
-
Elisabetta Abruzzese, MD · Ospedale S. Eugenio Roma
-
Vincenzo Accurso, MD · A.U. Policlinico "Paolo Giaccone" Palermo
-
Mario Annunziata, MD · Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli" Napoli
-
Francesco Passamonti, MD · Ospedale di Circolo e Fondazione Macchi Varese, ASST dei Sette Laghi Varese
-
Massimo Bonifacio, MD · Istituti Ospitalieri di Verona- Policlinico G.B. Rossi Verona
-
Giovanni Caocci, MD · CTMO - Ospedale "Businco" Cagliari
-
Francesca Lunghi, MD · Ospedale Milano S. Raffaele Milano
-
Chiara Elena, MD · Fondazione IRCCS Policlinico San Matteo di Pavia
-
Monica Crugnola, MD · Az Ospedaliera Universitaria Parma
-
Sara Galimberti, MD · Azienda Ospedaliera Pisana Pisa
-
Alessandra Iurlo, MD · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano Milano
-
Luciano Levato, MD · Az. Ospedaliera Pugliese - Ciaccio (AOPC) Catanzaro
-
Maria Cristina Miggiano, MD · Azienda ULSS 8 "Berica" Ospedale San Bortolo Vicenza
-
Patrizia Pregno, MD · A.O. Città della Salute e della Scienza di Torino S. G.Battista Torino
-
Davide Rapezzi, MD · Ospedale Cuneo
-
Rosaria Sancetta, MD · Ospedale dell'Angelo Mestre Venezia
-
Fabio Stagno, MD · P.O. Gaspare Rodolico, Catania
-
Luigia Luciano, MD · Azienda Ospedaliera Universitaria-Università degli Studi di Napoli "Federico II"
-
Carmen Fava, MD · A.S.O. Ordine Mauriziano, P.O. Umberto I Torino
-
Philipp leCoutre, MD · Charité University of Berlin · Medical Department, Division of Oncology and Hematology
-
Susanne Saussele, MD · University of Mannheim
-
Sarit Assouline, MD · Jewish General Hospital
-
Alberto Álvarez-Larrán, MD · University Hospital Clínic de Barcelona
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-30
- Primary Completion
- 2021-09-30
- Completion
- 2023-08-14
Countries
- Canada
- Germany
- Italy
- Spain
Study Locations
More Related Trials
-
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia
NCT00511303 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01185886 ·Status: UNKNOWN
-
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
NCT03045120 ·Status: COMPLETED
-
Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia
NCT03131986 ·Status: UNKNOWN
-
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
NCT02388048 ·Status: COMPLETED ·Phase: PHASE2
-
Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission
NCT05439889 ·Status: RECRUITING
-
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation
NCT03153514 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment of Acute Myeloblastic Leukemia in Younger Patients
NCT00390715 ·Status: COMPLETED
-
National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent
NCT02903277 ·Status: UNKNOWN
-
Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients
NCT01578213 ·Status: COMPLETED ·Phase: PHASE4
-
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
NCT04626024 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase
NCT00514969 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors
NCT01752062 ·Status: UNKNOWN
-
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
NCT06368414 ·Status: RECRUITING ·Phase: PHASE2
-
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
NCT01860456 ·Status: COMPLETED
-
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
NCT03610971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Decitabine, Cytarabine, GCSF for Refractory AML/MDS
NCT00740181 ·Status: TERMINATED ·Phase: PHASE2
-
Study Conducted Among Patients With CML
NCT05476562 ·Status: COMPLETED
-
Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
NCT06121765 ·Status: NOT_YET_RECRUITING
-
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
NCT01826214 ·Status: COMPLETED ·Phase: PHASE2
-
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT01550185 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
NCT02973191 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
NCT05310591 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Identification of BCR::ABL1 Mutations by Digital PCR in CML
NCT07158294 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy
NCT01490853 ·Status: COMPLETED